Search

Your search keyword '"Gao Lichang"' showing total 7 results
Start Over Author "Gao Lichang"
7 results on '"Gao Lichang"'

3. 'PP-type' self-assembling peptides with superior rheological properties

Author

Feng Jinhui, Chunxia Zhang, Zhao Chengru, Zhang Shang, Li Fangmin, Liu Yuanxue, Gao Lichang, Pin Wang, and Zhang Xudong

Subjects
chemistry.chemical_classification, Hemostatic Agent, Aqueous solution, Chemistry, General Engineering, Bioengineering, Sequence (biology), Nanofiber scaffold, Peptide, General Chemistry, Combinatorial chemistry, Atomic and Molecular Physics, and Optics, Rheology, Self assembling, General Materials Science, Solubility
Abstract

The ionic-complementary self-assembling peptides discovered by Zhang Shuguang have solution-to-gel (sol-gel) transition capacity and one such peptide RADA16 has been commercialized into hemostatic agents. However, their sol-gel transition ability was not obvious because the peptide aqueous solution with a concentration greater than 1% w/v appeared to be thick and viscous. The current report describes PP-type self-assembling peptides. In addition to the ionic-complementary sequence, they have prolines at both ends of the sequence. This feature has led to better solubility, lower viscosity of the peptide solution, and simplified synthesis and purification processes while maintaining the great gelling performance of the ionic-complementary peptides. The PP-type peptides self-assembled into a well-organized nanofiber scaffold as shown by TEM. Among the PP-type peptides, the PRVDP9 sequence peptide was tested as a hemostatic agent and a mucosal elevating agent. The results were comparable to the classic RADA16. The PP-type self-assembling peptides have superior sol-gel transition ability. Therefore, it is predicted that they will be more suitable to be transported through catheters or endoscopes and have higher commercialization potential as compared with the classic self-assembling peptide sequences.

Published
2021
Full Text
View/download PDF

7. Expression of CD4 + T Cells in Myeloproliferative Diseases and the Effect of Ruxolitinib Treatment on Prognosis.

Author

Song X, Dong S, Yang Y, Zhang C, Sun J, Zhang J, Gao L, and Liu J

Subjects
Humans, Prognosis, Male, Female, Middle Aged, Aged, Spleen pathology, Spleen drug effects, Adult, Nitriles therapeutic use, Pyrimidines therapeutic use, Pyrazoles therapeutic use, Pyrazoles pharmacology, Myeloproliferative Disorders drug therapy, Myeloproliferative Disorders genetics, CD4-Positive T-Lymphocytes, Janus Kinase 2 genetics, Janus Kinase 2 metabolism
Abstract

Myeloproliferative disorders (MPDs) are rare diseases in which the bone marrow produces too many red, white, or platelets. Myeloproliferative disorders are neither acute nor leukaemia. To study ruxolitinib's effect on MPD therapy and CD4 + T cell expression. In total, 66 JAK2V617F-positive MPD patients were admitted to our hospital. The patients were randomly assigned to control and research groups (each 33). Hydroxyurea pills were given to the control group and ruxolitinib to the observation group. The MPN-10 assesses 10 of the most clinically relevant symptoms, including fatigue and generates a Total Symptom Score (TSS). In addition, by comparing myelofibrosis (MF), spleen length, JAK2V617F gene expression, peripheral blood lymphocyte and T cell levels, and prognostic levels, analyze the shortcomings of each group. Post-treatment, MPN-10, MF, and spleen length diameter were reduced in both groups (P < 0.05), with the study group showing a higher reduction than the control group (P < 0.05). Compared to prior treatment, JAK2V617F gene expression was reduced in all groups after 6 months and a year of medication. The study category had a higher decrease in expression than the control group. After therapy, CD4 and CD4/CD8 levels rose, but CD8 and Treg levels decreased. The study group had increased CD4 and CD4/CD8 levels, whereas the control group had lower CD8 and Treg levels . The study group had a greater 1-year survival rate than the control group, but the control group had lower mortality and adverse event rates. In JAK2V617F-positive MPD patients, ruxolitinib reduces JAK2V617F gene expression, myelofibrosis, and therapeutic impact.

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results